Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 2, 2001, Pages 160-168

  Papadopoulou, M V ^a   Ji, M ^a   Bloomer, W D ^a  

^a Radiation Medicine Institute   (United States)

Author keywords

Chemotherapeutic agents; NLCQ 1; Potentiation; Tirapazamine

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; NLCQ 1; PACLITAXEL; QUINOLINE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLONOGENIC ASSAY; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ETOPOSIDE; FEMALE; FLUOROURACIL; IMIDAZOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MELPHALAN; MICE; MICE, INBRED BALB C; PACLITAXEL; QUINOLINES; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0034905940     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100290     Document Type: Article

References (42)

1. Tumor-specific, schedule-dependent interaction between tirapazamine (SR4233) and cisplatin
2. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine
3. Skin ulceration potential of paclitaxel in a mouse skin model in vivo
4. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice
5. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay
6. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers
7. 2 predicts survival in advanced cancer of the uterine cervix
8. Hypoxia and radiation response in human tumors
9. Enhancement of alkylating agent activity by SR-4233 in FSalIC murine fibrosarcoma
10. The effect of systemic hyperthermia on melphalan pharmacokinetics in mice
11. Hypoxic cells as specific drug targets for chemotherapy
12. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
13. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts
14. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumors
15. Comparative adverse effect profiles of platinum drugs (review)
16. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer
17. Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo
18. Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents
19. Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents
20. THNLA-1 as radio/chemosensitizer of EMT6 tumors in mice
21. THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo
22. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound; cytotoxicity and reduction studies
23. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent with enhanced hypoxic selectivity
24. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer. I.
25. 9-[3-(2-Nitro-1-imidazolyl)propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer: Mechanistic studies. II.
26. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo
27. Mechanistic studies regarding the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro
28. Potentiation of chemotherapeutic drugs by the bioreductive compound NLCQ-1 against SCCVII tumors in mice
29. In vitro schedule-dependent potentiation of Taxol, 5-FU and cisDDP by the hypoxic cytotoxin NLCQ-1. Comparison with tirapazamine
30. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin
31. Tirapazamine: A hypoxia activated topoisomerase II inhibitor
32. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative
33. Therapeutic attack of hypoxic cells of solid tumors: Presidential address
34. Modification of chemotherapy by nitroimidazoles
35. The in situ tumor response to combinations of cyclophosphamide and tirapazamine
36. Potentiation of cisplatin activity by the bioreductive agent tirapazamine
37. Sensitization of cancer chemotherapeutic agents by nitroheterocyclics
38. Potentiation of alkylating chemotherapy by dual function nitrofurans in multicell spheroids and solid tumors
39. HPLC analysis and murine pharmacokinetics of the cytotoxic bioreductive agent NLCQ-1 (NSC 709257)
40. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study
41. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
42. DNA topoisomerase II as the primary target of antitumor anthracyclines